Indrayani Biotech Ltd
BSE:526445
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Indrayani Biotech Ltd
BSE:526445
|
IN |
Balance Sheet
Balance Sheet Decomposition
Indrayani Biotech Ltd
Indrayani Biotech Ltd
Balance Sheet
Indrayani Biotech Ltd
| Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
7
|
15
|
30
|
6
|
3
|
|
| Cash |
1
|
1
|
0
|
0
|
3
|
|
| Cash Equivalents |
6
|
15
|
30
|
6
|
0
|
|
| Short-Term Investments |
0
|
0
|
97
|
297
|
0
|
|
| Total Receivables |
79
|
154
|
323
|
724
|
1 101
|
|
| Accounts Receivables |
48
|
141
|
300
|
395
|
587
|
|
| Other Receivables |
31
|
13
|
24
|
328
|
514
|
|
| Inventory |
11
|
15
|
122
|
424
|
413
|
|
| Other Current Assets |
0
|
5
|
203
|
297
|
262
|
|
| Total Current Assets |
96
|
189
|
775
|
1 450
|
1 779
|
|
| PP&E Net |
253
|
259
|
479
|
594
|
600
|
|
| PP&E Gross |
0
|
0
|
0
|
594
|
600
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
392
|
435
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
38
|
38
|
233
|
233
|
233
|
|
| Note Receivable |
0
|
0
|
16
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
2
|
2
|
2
|
|
| Other Long-Term Assets |
13
|
27
|
54
|
61
|
64
|
|
| Other Assets |
38
|
38
|
233
|
233
|
233
|
|
| Total Assets |
401
N/A
|
514
+28%
|
1 560
+203%
|
2 340
+50%
|
2 679
+14%
|
|
| Liabilities | ||||||
| Accounts Payable |
33
|
58
|
227
|
374
|
236
|
|
| Short-Term Debt |
74
|
111
|
317
|
399
|
700
|
|
| Current Portion of Long-Term Debt |
0
|
4
|
58
|
20
|
16
|
|
| Other Current Liabilities |
11
|
22
|
116
|
78
|
72
|
|
| Total Current Liabilities |
118
|
195
|
719
|
871
|
1 025
|
|
| Long-Term Debt |
82
|
73
|
357
|
707
|
654
|
|
| Deferred Income Tax |
0
|
0
|
0
|
10
|
0
|
|
| Minority Interest |
4
|
4
|
67
|
91
|
274
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
1
|
|
| Total Liabilities |
203
N/A
|
272
+34%
|
1 009
+270%
|
1 668
+65%
|
1 954
+17%
|
|
| Equity | ||||||
| Common Stock |
342
|
342
|
435
|
455
|
455
|
|
| Retained Earnings |
145
|
101
|
116
|
91
|
69
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
126
|
201
|
|
| Total Equity |
197
N/A
|
242
+23%
|
551
+128%
|
672
+22%
|
725
+8%
|
|
| Total Liabilities & Equity |
401
N/A
|
514
+28%
|
1 560
+203%
|
2 340
+50%
|
2 679
+14%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
34
|
34
|
34
|
46
|
46
|
|